News

In May 2004, the two companies forged a strategic antibody alliance to jointly develop new antibody-based therapeutics against a range of illnesses. As part of the collaboration, Novartis

BioSeek will apply its proprietary BioMap systems in an effort to characterize the mechanisms of action of the leukocyte selective anti-inflammatory drugs (LSAIDs), which make up Inflazyme's respiratory

Prezista, co-administered with 100mg ritonavir (Prezista/rtv) and with other antiretroviral agents, is indicated for the treatment of HIV infection in antiretroviral treatment-experienced adult patients, such as those with

The trial, conducted by DeCode under a research collaboration and licensing agreement with Cephalon, was based upon DeCode's discovery of variants in the gene encoding the MAP3K9 kinase

TACI-Ig is a soluble fusion protein that neutralizes molecules implicated in the pathogenesis of several autoimmune diseases. TACI-Ig appeared to be well tolerated across the full range of

As the first company to file an abbreviated new drug application for the 5mg, 10mg, 20mg and 40mg strengths, Teva has been awarded 180 days of marketing exclusivity.

The data, presented at the 88th annual meeting of the Endocrine Society, highlights the potential of this marker, but the company said that more research is needed to

A randomized, double-blind study of 37 healthy subjects was conducted to evaluate the efficacy of VEC-162 (10, 20, 50 and 100mg) in a model of transient insomnia. The

ALTU-238 is being developed as a subcutaneously administered, once-per-week formulation of human growth hormone. The company hopes that the once-per-week dosing of the product will offer a benefit